The Novo Nordisk Foundation announced that the government will provide up to $265 million for an initiative to improve vaccines against respiratory diseases. Novo Nordisk’s huge profits from Wegovy, a wildly successful slimming drug, have swelled the foundation’s coffers, potentially making it a major philanthropist and investor in environmental, social and governance issues.